cabozantinib,atezolizumab
exelixis,roche
['cosmic021', 'crpc']
my 1st mtg at #asco22: investigator mtg for #contact2, led by . impt trial that builds on #cosmic021 data showing activity w cabo/atezo in mcrpc. 
@cityofhope & @cityofhopeoc prof w focus on #kidneycancer, #prostatecancer, #bladdercancer & 90s rock. RTs not endorsements. COI: https://t.co/L7ihnCjLz5